BioMarin Pharmaceutical Inc. (BMRN)

105.14
1.30 1.30
NASDAQ : Health Technology
Prev Close 103.82
Open 104.68
Day Low/High 103.64 / 104.95
52 Wk Low/High 75.81 / 106.74
Volume 39.24K
Avg Volume 1.18M
Exchange NASDAQ
Shares Outstanding 177.59M
Market Cap 18.84B
EPS -0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)
BioMarin And Believe Limited Announce Selection Of 25 High School Students To Perform In First-of-its-Kind 'Hemophilia: The Musical'

BioMarin And Believe Limited Announce Selection Of 25 High School Students To Perform In First-of-its-Kind 'Hemophilia: The Musical'

The young adults, each affected by a bleeding disorder, will perform in the Broadway-style musical upon completion of the 'Breaking Through!' Musical Theater Intensive workshop

Forbes Names BioMarin Among World's Best Employers

Forbes Names BioMarin Among World's Best Employers

Company listed amongst top five biotech employers

BioMarin To Participate In Two Investor Conferences In October

BioMarin To Participate In Two Investor Conferences In October

Cantor Fitzgerald Global Healthcare Conference on October 1 in New York City

BioMarin Announces 20 Poster Presentations At Society For The Study Of Inborn Errors Of Metabolism (SSIEM) Symposium 2018

BioMarin Announces 20 Poster Presentations At Society For The Study Of Inborn Errors Of Metabolism (SSIEM) Symposium 2018

Updated results from Phase 1/2 program for tralesinidase alfa (formerly BMN 250)

BioMarin To Participate In Three Investor Conferences In September

BioMarin To Participate In Three Investor Conferences In September

- Citi's 13th Annual Biotech Conference on September 5-6 in Boston

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ASPS, BMRN, CNHI, GTIM, JHX, NXEOU, PICO, USAP, VTSI, WUBA Downgrades: ABCB, CTRP, FDP, GBLI, MHLD, PDLI, SMCI, TV Initiations: BHF, PLXP Read on to get TheStreet Quant Ratings' detailed report:

3 Biotech Stock Favorites to Bet on Today: Top Analysts

3 Biotech Stock Favorites to Bet on Today: Top Analysts

Follow the experts. These biotech stocks have Wall Street's best analysts getting bullish.

Jim Cramer: 5 Sectors to Buy on This 'Turkish Contagion' Market Drop

Jim Cramer: 5 Sectors to Buy on This 'Turkish Contagion' Market Drop

It is all about perception, and here are strong names to pick up on market weakness.

BioMarin Announces Second Quarter 2018 Results

BioMarin Announces Second Quarter 2018 Results

- Total Revenues of $372.8 million in the Quarter

Charts: BioMarin Pharmaceutical Could Rise 30% From Here

Charts: BioMarin Pharmaceutical Could Rise 30% From Here

I have not seen a bullish breakout from a large base pattern in a while.

BioMarin Paces a Very Strong Biotech Group

BioMarin Paces a Very Strong Biotech Group

Here's how BMRN's chart looks after its blistering gains.

Chart of the Day: BioMarin Pharmaceutical

BMRN is pacing the very strong biotech group.

BioMarin To Host Second Quarter 2018 Financial Results Conference Call And Webcast On Thursday, August 2 At 4:30pm ET

BioMarin To Host Second Quarter 2018 Financial Results Conference Call And Webcast On Thursday, August 2 At 4:30pm ET

SAN RAFAEL, Calif., July 11, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc.

BioMarin Partners With Believe Limited For 'Breaking Through!' Musical Theater Intensive

BioMarin Partners With Believe Limited For 'Breaking Through!' Musical Theater Intensive

First-of-Its-Kind Musical to Help Empower the Bleeding Disorder Community to Find and Use their Voices through the Power of Music

BioMarin Announces First Recipients Of RARE Scholars Scholarship Program

BioMarin Announces First Recipients Of RARE Scholars Scholarship Program

Five Students with Rare Genetic Diseases Receive a Total of $20,000 for Higher Education

BioMarin Doses First Participant In Phase 2 Study Of Vosoritide For Treatment Of Infants And Young Children With Achondroplasia

BioMarin Doses First Participant In Phase 2 Study Of Vosoritide For Treatment Of Infants And Young Children With Achondroplasia

SAN RAFAEL, Calif., June 14, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc.

BioMarin Receives Milestone Payments From Pfizer For Talazoparib

BioMarin Receives Milestone Payments From Pfizer For Talazoparib

SAN RAFAEL, Calif., June 7, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc.

Probing the Long Side of BioMarin

Probing the Long Side of BioMarin

Latest surge boosts chances of breakout in shares of BioMarin.

BioMarin Pharmaceutical Is Doing Better but Patience Is Needed

BioMarin Pharmaceutical Is Doing Better but Patience Is Needed

The upswing is welcomed but it still is not an important breakout of the two-year sideways pattern.

Stealth Rally: Cramer's 'Mad Money' Recap (Thursday 5/10/18)

Stealth Rally: Cramer's 'Mad Money' Recap (Thursday 5/10/18)

Take one part great earnings and one part tremendous skepticism, add in low inflation and you end up with this astonishing stealth rally. Jim Cramer explains it.

What to Expect From Trump's Speech on Drug Prices on Friday

What to Expect From Trump's Speech on Drug Prices on Friday

Since taking office, President Trump has talked big on reining in drug prices, but the administration's lack of action leaves most expecting a May 11 speech that tastes like a nothing burger.

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists

Jim Cramer and our other experts discus China and tariffs, the 10 year nearing 3%, technical analysis, and biotech stocks.

Here's My Take on Biotech Stocks

Here's My Take on Biotech Stocks

I think M&A activity will pick up markedly going forward across the industry.

Markets Keep Eye on China Presidential Speech; Biotechs Bounce -- ICYMI

Markets Keep Eye on China Presidential Speech; Biotechs Bounce -- ICYMI

Here's what you need to know for Monday, April 9.

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

While Donald Trump's tweets can shake up pharmaceutical stocks, history suggests that investors have little to fear from the president's drug pricing rhetoric.

5 Top Stocks With 100% Buy Ratings Right Now

5 Top Stocks With 100% Buy Ratings Right Now

These five 'Strong Buy' stocks boast a double whammy of only buy ratings and big upside potential. After the market's recent plunge, this list is quite handy.

Why I Stay Very Focused on My Individual Stocks

Why I Stay Very Focused on My Individual Stocks

I do not need to come up with any grand arguments for a bullish or bearish bias. It happens by default.

7 Winners and Losers From Biggest Biotech Conference of 2017

7 Winners and Losers From Biggest Biotech Conference of 2017

Here are how some of the conference presenters are performing on the market Wednesday

TheStreet Quant Rating: C- (Hold)